Zenabis to Supply Premium Recreational Cannabis to Alberta
20 Feb, 2019, 06:00 ET
Becomes eighth province/territory for Zenabis products
VANCOUVER, Feb. 20, 2019 /CNW/ - Zenabis Global Inc. ("Zenabis") (TSXV: ZENA) today announced that it will formally enter the Alberta recreational cannabis market, supplying retailers throughout the province through a Supply Agreement it has entered into with the Alberta Gaming, Liquor & Cannabis Commission (AGLC). Zenabis will supply seven strains of its premium, adult-use Namastetm products beginning Q1 2019.
Alberta represents the eighth province/territory that Zenabis will supply, and builds on Zenabis' significant recent momentum in developing sales and marketing channels for its complete range of products. On February 4, 2019 Zenabis announced an agreement with Shoppers Drug Mart, adding a major new retail channel to serve medical patients across Canada.
"We are thrilled to offer our products to Alberta consumers, and to grow our distribution platform in a significant new market," said Andrew Grieve, Chief Executive Officer of Zenabis. We look forward to continuing the rapid expansion of our distribution relationships in Canada and abroad."
In addition to Alberta, Zenabis has distribution relationships with government and third-party retailers/distributors British Columbia, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island, and the Yukon Territory.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Zenabis is a significant licensed cannabis cultivator of medical and recreational cannabis, and employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta and Langley, B.C.; and Stellarton, Nova Scotia. Zenabis currently owns 3.5 million square feet of facility space that can, upon full conversion, be dedicated to cannabis production.
If all facility space is fully built out and dedicated to production, Zenabis will own, and have access to, 660,000 square feet of high quality indoor cannabis production space, as well as 2.1 million square feet of greenhouse space at its Langley facility that is intended to be dedicated to cannabis production, with this cannabis production capacity strategically located on Canada's East and West coasts. These facilities, if fully converted for cannabis production, would have the design capacity to yield 479,300kg of dried cannabis annually, for both national and international market distribution. An additional 700,000 square feet of greenhouse space will be used to continue the existing propagation business, and this will be converted at such a time that is beneficial to the strategic position of the company. The Zenabis brand name is used among the medical market, while Namaste is used to service the recreational market.
The management team at Zenabis has significant experience in finance, agriculture, technology, pharmaceutical sales, consumer packaged goods, international distribution and brand marketing. Zenabis' leadership is backed by the expertise of a Chief Operating Officer, Chief Growing Officer, a Chief Science Officer and Chief Medical Officer.
Forward Looking Information
This news release contains statements that may constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information may include, among others, statements regarding the future plans, costs, objectives or performance of Zenabis, or the assumptions underlying any of the foregoing. In this news release, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the sale of Zenabis products in Alberta pursuant to the supply agreement; and the conversion, expansion and optimization of Zenabis' facilities. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Zenabis' control. These risks, uncertainties and assumptions include, but are not limited to, those described Zenabis Management Information Circular dated November 23, 2018, a copy of which is available on SEDAR at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Furthermore, any forward-looking information with respect to available space for cannabis production is subject to the qualification that management of Zenabis may decide not to use all available space for cannabis production, and the assumptions that any construction or conversion would not be cost prohibitive, required permits will be obtained and the labour, materials and equipment necessary to complete such construction or conversion will be available. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Zenabis does not intend, nor undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws.
For more information, visit: https://www.zenabis.com.
SOURCE Zenabis Global Inc.
For further information: Media Relations: [email protected], 1-844-523-8679; Investor Relations: Shobana Thaya, Zenabis Global Inc., [email protected], 1-844-523-8679
Share this article